Treatment of murine cytomegalovirus salivary-gland infection by combined therapy with ganciclovir and thymic humoral factor γ2

Palmon, Aaron; Blagerman, S. K.; Tel-Or, Shoshana; Pecht, M; Trainin, Nathan; Burstein, Yigal; Rager-Zisman, Bracha

doi:10.1016/s0166-3542(96)00996-5

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The peptide was shown to account for the observed effects of crude thymus extracts in stimulating T-cell functions [2,3] and interleukin 2 (IL-2) production [4]. It has also been shown to be of value for the treatment of some viral diseases [5], immune-insufficiency conditions [3] and as an adjunct to chemotherapy in cancer treatment [6].…”

Section: Introductionmentioning

confidence: 99%

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

Martignoni

Benedetti

Davey

et al. 2020

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

Martignoni

Benedetti

Davey

et al. 2020

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

View full text Add to dashboard Cite

“…In human trials, lymphocytes primed against CMV have been harvested from healthy individuals and transfused into immunosuppressed patients to reduce peripheral illness (47,56,66). These studies support adoptive immune therapy as a means of preventing or alleviating existing infection in peripheral organs; however, diversity in organ clearance mechanisms remains a factor (24,44,48). In terms of immunity against viral infection, the brain is considered a unique organ, with different and sometimes absent expression of the major histocompatibility complex (MHC) cell surface molecules that normally bind and present antigenic peptides on the surfaces of cells for recognition (binding) by the antigen-specific T-cell receptors of lymphocytes.…”

mentioning

confidence: 99%

CD4⁺T-Cell Reconstitution Reduces Cytomegalovirus in the Immunocompromised Brain

Reuter¹,

Wilson²,

Idoko³

et al. 2005

J Virol

View full text Add to dashboard Cite

Cytomegalovirus (CMV) infection is the most common opportunistic infection of the central nervous systemin patients with human immunodeficiency virus or AIDS or on immunosuppressive drug therapy. Despite medical management, infection may be refractory to treatment and continues to cause significant morbidity and mortality. We investigated adoptive transfer as an approach to treat and prevent neurotropic CMV infection in an adult immunodeficient mouse model. SCID mice were challenged with intracranial murine CMV (MCMV) and reconstituted with MCMV-or vesicular stomatitis virus (VSV)-sensitized splenocytes, T cells, or T-cell subsets. T cells labeled with vital dye or that constitutively generated green fluorescent protein (GFP) were identified in the brain as early as 3 days following peripheral transfer. Regardless of specificity, activated T cells localized to regions of the brain containing CMV, however, only those specific for CMV were effective at clearing virus. Reconstitution with unsorted MCMV-immune splenocytes, enriched T-cell fractions, or CD4؉ cells significantly reduced virus levels in the brain within 7 days and also prevented clinical disease, in significant contrast with mice given VSV-immune unsorted splenocytes, MCMV-immune CD8 ؉ T cells, and SCID control mice. Results suggest CMV-immune T cells (particularly CD4 ؉ ) rapidly cross the blood-brain barrier, congregate at sites of specific CMV infection, and functionally eliminate acute CMV within the brain. In addition, when CMV-immune splenocytes were administered prior to a peripheral CMV challenge, CMV entry into the immunocompromised brain was prevented. Systemic adoptive transfer may be a rapid and effective approach to preventing CMV entrance into the brain and for reducing neurotropic infection.

show abstract

Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland

Rouvio

Dvorkin

Amir-Kroll

et al. 2005

Vaccine

View full text Add to dashboard Cite

Treatment of murine cytomegalovirus salivary-gland infection by combined therapy with ganciclovir and thymic humoral factor γ2

Cited by 4 publications

References 39 publications

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

CD4⁺T-Cell Reconstitution Reduces Cytomegalovirus in the Immunocompromised Brain

Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland

Contact Info

Product

Resources

About

Treatment of murine cytomegalovirus salivary-gland infection by combined therapy with ganciclovir and thymic humoral factor γ2

Cited by 4 publications

References 39 publications

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

Degradation of thymic humoral factor γ2 in human, rat and mouse blood: An experimental and theoretical study

CD4+T-Cell Reconstitution Reduces Cytomegalovirus in the Immunocompromised Brain

Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland

Contact Info

Product

Resources

About

CD4⁺T-Cell Reconstitution Reduces Cytomegalovirus in the Immunocompromised Brain